Clinical Trial Update: A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) [Phase 1]

View source ↗

Summary

A Phase 1 study comparing intramuscular injections of AGN-151586 and OnabotulinumtoxinA for glabellar lines has completed and reported adverse events in adult p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Lines

Drugs mentioned

• AGN-151586
• OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: AbbVie | Conditions: Glabellar Lines | Phase 1 | Status: COMPLETED